Form 4: Cassava Sciences SVP & General Counsel, Robert Christopher Cook, Reports Stock Option Grant

Robert Christopher Cook, SVP & General Counsel of Cassava Sciences, reports the acquisition of stock options.

Summary

• On September 6, 2024, Robert Christopher Cook, the SVP & General Counsel of Cassava Sciences, acquired 100,000 stock options.
• The options have an exercise price of $26.91.
• The stock options vest over 2 years, with 50% cliff vesting 1-year after the grant date and the remaining 50% cliff vesting 2-years after the grant date.
• The options expire on September 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The stock option grant itself is neither overwhelmingly positive nor negative.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of 50% after one year and 50% after two years is a fairly typical vesting arrangement.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.
• There is no immediate impact on employees, customers, suppliers, or creditors.

Key Dates